An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors

• ClinicalTrials.gov Identifier: NCT01678690
• Recruitment Status: Completed
• First Posted: September 5, 2012
• Last Update Posted: September 2, 2016
• Sponsor: InnoPharmax Inc.
• Information provided by (Responsible Party): InnoPharmax Inc.

Study Description

Brief Summary:

Open-label, Phase 0, dose-escalation study of 3 successive cohorts (3 subjects per cohort), to determine and characterize the plasma PK of gemcitabine HCl oral formulation (D07001-F4) administered once on Day 1 with 7 Days of study follow-up. In addition, oral tolerability and safety will also be assessed during this 1-week period.

Condition or disease	Intervention/treatment	Phase
Malignant Tumors	Drug: Gemcitabine HCl Oral Formulation	Early Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 11 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Official Title: An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
• Study Start Date: August 2012
• Actual Primary Completion Date: April 2014
• Actual Study Completion Date: April 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: Gemcitabine HCl Oral Formulation; Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period	Drug: Gemcitabine HCl Oral Formulation; Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period; Other Name: D07001-F4

Outcome Measures

Primary Outcome Measures :

1. gemcitabine (dFdC) and difluorodeoxyuridine (dFdU) plasma concentration and gemcitabine triphosphate (dFdCTP) concentration in PBMC [ Time Frame: Day 1-5 ]

Secondary Outcome Measures :

1. the proportion of subjects experiencing adverse events all grades, change from baseline in clinical laboratory test results, vital sign measurements, and physical examination findings [ Time Frame: Day 1-8 (+/- 1) days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female subjects aged 18 years and older.
2. Signed and dated informed consent form.
3. Subjects with malignancies with histological or pathologic confirmation and who are clinically stable.
4. History of treatment with at least 1 cytotoxic chemotherapy regimen for the current malignancy.
5. If the subject has received cytotoxic chemotherapy within the past 14 days, the subject is beyond the nadir of white blood cell and platelet counts.
6. At least 28 days have elapsed since the subject's prior radiotherapy or any major surgery (excluding diagnostic biopsy or venous access device placement).
7. World Health Organization (WHO) performance status 0 to 2
8. Subject has an ANC ≥1500 cells/mm³, platelet count ≥ 100,000 cells/mm³, and hemoglobin ≥ 9 g/dL.
9. Subject has adequate liver function demonstrated by transaminases within normal limits (aspartate transaminase and alanine transaminase), total bilirubin ≤ 1.5 mg/dL (unless due to Gilbert's syndrome), albumin ≥ 2.5 g/dL, international normalized ratio [INR] < 1.5).
10. Subject has adequate renal function: serum creatinine ≤ 1.5 x upper limit of normal.
11. Subject has a life expectancy >24 weeks.
12. If a women of child-bearing potential, subject has a negative pregnancy test and is not breast-feeding.
13. If a women of child-bearing potential, subject is using a medically acceptable form of birth control prior to screening and for the duration of their study participation and for 1 month after the end of the study.
14. Subject is willing to comply with protocol-required visit schedule and visit requirements and provide written informed consent.

Exclusion Criteria:

1. Subject has rapidly progressive disease or rapid clinical deterioration as assessed by the Investigator.
2. Subject is receiving full-dose (therapeutic) anticoagulation therapy.
3. Subject is receiving concomitant radiotherapy.
4. Subject is intolerant or allergic or has a known hypersensitivity to gemcitabine.
5. Subject has clinically significant cardiovascular disease (for example: uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association Grade 2 or greater).
6. Subject has uncontrolled serious cardiac arrhythmia.
7. Subject has known active brain metastases, or any leptomeningeal metastases.
8. Subject has a history of drug or alcohol abuse within last year.
9. Subject has documented cerebrovascular disease.
10. Subject has a seizure disorder not controlled on medication.
11. Subject received an investigational agent within 30 days of screening.
12. Subject received systemic treatment for infection within 14 days of screening.
13. Subject has known human immunodeficiency virus infection or viral hepatitis.
14. Subject has any other serious medical condition that, in the investigator's medical opinion, would preclude safe participation in a clinical trial.
15. Subject has gastrointestinal disease or prior gastrointestinal surgery that may interfere with adequate oral therapy absorption.

Contacts and Locations

Locations

United States, Georgia

Georgia Regents University- Cancer Center

Augusta, Georgia, United States, 30912

United States, Ohio

Gabrail Cancer Center Research

Canton, Ohio, United States, 44718

Gabrail Cancer Center Research

Dover, Ohio, United States, 44622

Taiwan

National Taiwan University Hospital

Taipei, Taiwan, 10048

Sponsors and Collaborators

InnoPharmax Inc.

Investigators

• Principal Investigator: Nashat Y. Gabrail, MD; Gabrail Cancer Center Research
• Principal Investigator: Sharad Ghamande, MD; Augusta University
• Principal Investigator: Chia-Chi Lin, MD; National Taiwan University Hospital

More Information

• Responsible Party: InnoPharmax Inc.
• ClinicalTrials.gov Identifier: NCT01678690
• Other Study ID Numbers: HR-11-001
• First Posted: September 5, 2012
• Last Update Posted: September 2, 2016
• Last Verified: August 2016

Additional relevant MeSH terms:

Neoplasms; Gemcitabine; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antiviral Agents; Anti-Infective Agents; Enzyme Inhibitors; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs